Navigation Links
Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010
Date:1/28/2010

UNION CITY, Calif., Jan. 28 /PRNewswire-FirstCall/ -- ABAXIS, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the fiscal quarter ended December 31, 2009.  

Record quarterly highlights include:

  • Revenues of $31.0 million, up 15% over last year's comparable quarter.
  • North America revenues of $24.9 million, up 9% over last year's comparable quarter.
  • Veterinary market sales of $23.9 million, up 33% over last year's comparable quarter.
  • Total medical and veterinary instrument sales of 1,212 units, up 37% over last year's comparable quarter.
  • Gross profit of $18.3 million, up 21% over last year's comparable quarter.

Other quarterly highlights include:

  • Total medical and veterinary reagent disc sales of $16.3 million, up 5% over last year's comparable quarter.
  • Operating income of $5.4 million, up 14% over last year's comparable quarter.
  • Cash, cash equivalents and investments as of December 31, 2009 of $93.2 million, compared to $74.6 million as of December 31, 2008.

Quarterly Results:  For the fiscal quarter ended December 31, 2009, Abaxis reported revenues of $31.0 million, as compared with revenues of $27.0 million for the comparable period last year, an increase of 15 percent.  Revenues from instrument sales, which include chemistry analyzers, hematology instruments, coagulation analyzers and i-STAT analyzers, increased by an aggregate of $485,000, or 6 percent, over the same period last year.  The company reported total medical and veterinary instrument sales of 1,212 units, up 37 percent over the same period last year.  Revenues from consumables, which include reagent discs, hematology reagent kits, coagulation cartridges, i-STAT cartridges and heartworm rapid tests, increased by an aggregate of $3.4 million, or 20 percent, over the same period last year.  The company reported net income of $3.4 million for the fiscal quarter ended December 31, 2009, which was flat in comparison to the same period in 2008.  The company's effective tax rate in the quarter ended December 31, 2009 was 37 percent, compared to 34 percent for the same period last year.  The company reported diluted net income per share of $0.15 (calculated based on 22,617,000 shares) for the third quarter of fiscal 2010, compared to $0.15 per share (calculated based on 22,264,000 shares) for the same period last year.

Nine-Month Results: For the nine-month period ended December 31, 2009, Abaxis reported revenues of $90.9 million, as compared with revenues of $79.2 million for the comparable period last year, an increase of 15 percent.  Revenues from instrument sales decreased by an aggregate of $1.4 million, or 6 percent, over the same period last year.  The company reported total medical and veterinary instrument sales of 2,971 units, up 23 percent over the same period last year.  Revenues from consumables increased by an aggregate of $11.6 million, or 23 percent, over the same period last year.  The company reported net income of $10.4 million, compared to $9.4 million for the same period last year.  The company's effective tax rate in the nine-month period ended December 31, 2009, was 39 percent, compared to 36 percent for the same period last year.  The company reported diluted net income per share of $0.46 (calculated based on 22,549,000 shares) for the nine months ended December 31, 2009, compared to $0.42 per share (calculated based on 22,325,000 shares) for the same period last year.

Other Reported Information:  Consumables revenues for the third quarter of fiscal 2010 were $20.1 million, up 20 percent over the $16.8 million reported for the same period last year.  Total sales in the medical market for the third quarter of fiscal 2010 were $5.2 million, a decrease of 28 percent compared to the same period last year, primarily due to a decrease in instrument sales to the U.S. government and distributors in North America.  Medical sales worldwide, excluding sales to the U.S. government, during the third quarter of fiscal 2010 were $4.8 million, a decrease of 21 percent compared to the same period last year, primarily due to inventory stock adjustments by distributors in North America.  Total sales in the veterinary market for the third quarter of fiscal 2010 were $23.9 million, an increase of 33 percent compared to the same period last year.  Veterinary reagent disc sales for the third quarter of fiscal 2010 were $12.8 million, an increase of 13 percent compared to the same period last year.  

Non-cash compensation expense recognized for share-based awards during the third quarter of fiscal 2010 was $1.4 million, compared to $465,000 for last year's comparable quarter.

Clint Severson, chairman and chief executive officer of Abaxis, commented, "We are pleased to report another solid quarter of double digit growth accompanied with strong operating margins.  Revenues grew 15% to a record of $31.0 million for the quarter, led by a 37% increase in instrument unit sales.  Operationally, gross margins continue at record levels, expanding 300 basis points versus the comparable quarter last year.  Our balance sheet remains healthy with $93.2 million in cash, cash equivalents, short- and long-term investments and no long-term debt."

Mr. Severson continued, "Our medical market sales team has made substantial progress in expanding our customer base by growing the installed base of Piccolo instruments, excluding the U.S. government.  With Piccolo instrument unit sales during the third quarter increasing 12% compared to our second quarter and 48% higher than the first quarter of the fiscal year, we are beginning to experience the benefits of our new strategic plan in addressing the medical point-of-care market.  Our goal is to remain focused on growing both our medical and veterinary markets by providing leading-edge technology and quality products to our customers allowing them to improve the way healthcare is delivered."

Conference Call

Abaxis has scheduled a conference call to discuss its results at 4:15 p.m. Eastern Time on Thursday, January 28, 2010.  Participants can dial (800) 860-2442 or (412) 858-4600 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the company's website at http://www.abaxis.com.  A replay of the call is available by visiting http://www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, access code 437292, through February 1, 2010.  This press release is also available prior to and after the call via Abaxis' website or the Securities and Exchange Commission's website at http://www.sec.gov.

About Abaxis

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements.  The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients.  The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples.  The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.  

Use of Non-GAAP Financial Measures

To supplement the financial statements presented in accordance with United States generally accepted accounting principles (GAAP), Abaxis uses operating income per share.  This non-GAAP financial presentation is not a measurement of performance under GAAP in the United States of America.  Management uses this measure in comparing Abaxis' operating results with historical performance and believes it provides meaningful and comparable information to management and investors to assist in their review of Abaxis' performance relative to prior periods and its competitors.

This press release includes, and our conference call will include, statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance of new or planned product offerings, process improvements and product manufacturing quality and efficiencies in future production of our products.  Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act.  These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts.  Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to the market acceptance of the company's products and the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with entering the human diagnostic market on a larger scale, risks related to the protection of the company's intellectual property or claims of infringement of intellectual property asserted by third parties, risks related to condition of the United States economy, risks involved in carrying of inventory and other risks detailed under "Risk Factors" in Abaxis' Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2009 and Abaxis' other periodic reports filed from time to time with the United States Securities and Exchange Commission.  Forward-looking statements speak only as of the date the statements were made.  Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Financial Tables on Following Pages

    
    
    ABAXIS, INC.
    Condensed Consolidated Statements of Operations
    (In thousands, except per share data)
    (Unaudited)
    
                                     Three Months Ended    Nine Months Ended
                                        December 31,         December 31,
                                        ------------         ------------
                                       2009       2008      2009       2008
                                       ----       ----      ----       ----
    
    Revenues                         $31,005    $26,964   $90,892    $79,224
    Cost of revenues                  12,709     11,859    37,590     35,274
                                      ------     ------    ------     ------
    Gross profit                      18,296     15,105    53,302     43,950
                                      ------     ------    ------     ------
    
    Operating expenses:
         Research and development      2,835      2,037     8,002      6,116
         Sales and marketing           7,486      6,061    21,428     18,382
         General and administrative    2,552      2,241     7,739      5,855
                                       -----      -----     -----      -----
    Total operating expenses          12,873     10,339    37,169     30,353
                                      ------     ------    ------     ------
    
    Income from operations             5,423      4,766    16,133     13,597
    Interest and other income
     (expense), net                      (11)       352       795      1,140
                                         ---        ---       ---      -----
    Income before income tax
     provision                         5,412      5,118    16,928     14,737
    Income tax provision               1,982      1,762     6,545      5,308
                                       -----      -----     -----      -----
    Net income                        $3,430     $3,356   $10,383     $9,429
                                      ======     ======   =======     ======
    
    Net income per share:
      Basic net income per share       $0.16      $0.15     $0.47      $0.43
                                       =====      =====     =====      =====
      Diluted net income per share     $0.15      $0.15     $0.46      $0.42
                                       =====      =====     =====      =====
    
    Shares used in the calculation
     of net income per share:
      Weighted average common shares
       outstanding - basic            22,035     21,879    22,002     21,798
      Weighted average common shares
       outstanding - diluted          22,617     22,264    22,549     22,325
    
    
    
    
    
    ABAXIS, INC.
    Condensed Consolidated Balance Sheets
    (Unaudited and in thousands)
    
                                                    December 31,  March 31,
                                                       2009         2009
                                                       ----         ----
    Current assets:
      Cash and cash equivalents                      $48,282      $49,237
      Short-term investments                          21,284       20,776
      Receivables, net                                21,951       21,983
      Inventories                                     17,551       15,735
      Prepaid expenses                                 1,600          957
      Net deferred tax asset, current                  3,576        4,676
                                                       -----        -----
        Total current assets                         114,244      113,364
      Long-term investments                           23,605        4,886
      Property and equipment, net                     14,571       14,798
      Intangible assets, net                           4,744        5,175
      Other assets                                        76           24
      Net deferred tax asset, non-current              2,653        2,464
                                                       -----        -----
       Total assets                                 $159,893     $140,711
                                                    ========     ========
    
    Current liabilities:
      Accounts payable                                $7,634       $3,963
      Accrued payroll and related expenses             4,678        3,698
      Accrued taxes                                      481           34
      Other accrued liabilities                        1,275        1,116
      Deferred revenue                                 1,128        1,024
      Warranty reserve                                 1,373        1,714
                                                       -----        -----
        Total current liabilities                     16,569       11,549
                                                      ------       ------
    
    Non-current liabilities:
      Deferred rent                                        -          137
      Deferred revenue                                 1,402        1,550
      Warranty reserve                                   245          583
                                                         ---          ---
        Total non-current liabilities                  1,647        2,270
                                                       -----        -----
    
    Shareholders' equity:
      Common stock                                   122,248      117,846
      Retained earnings                               19,429        9,046
                                                      ------        -----
        Total shareholders' equity                   141,677      126,892
                                                     -------      -------
        Total liabilities and shareholders' equity  $159,893     $140,711
                                                    ========     ========
    
    
    
    
    
    Non-GAAP Operating Income Per Share
    (In thousands, except per share data)
                                          
                                      Three Months Ended   Nine Months Ended
                                         December 31,        December 31,
                                        --------------       ------------
                                        2009      2008      2009      2008
                                        ----      ----      ----      ----
    Shares used in the calculation of
     operating income per share
     (non-GAAP):
      Weighted average common
       shares outstanding - basic      22,035    21,879    22,002    21,798
      Weighted average common
       shares outstanding - diluted    22,617    22,264    22,549    22,325
    
    Non-GAAP operating income per
     share - basic                      $0.25     $0.22     $0.73     $0.62
                                        =====     =====     =====     =====
    Non-GAAP operating income per
     share - diluted                    $0.24     $0.21     $0.72     $0.61
                                        =====     =====     =====     =====
    
    
    Revenues by Geographic Region
    (In thousands)
                                      Three Months Ended   Nine Months Ended
                                         December 31,        December 31,
                                        --------------       ------------
                                        2009      2008      2009      2008
                                        ----      ----      ----      ----
    North America                     $24,907   $22,852   $73,792   $65,560
    International                       6,098     4,112    17,100    13,664
                                        -----     -----    ------    ------
    Total revenues                    $31,005   $26,964   $90,892   $79,224
                                      =======   =======   =======   =======
    
    
    Revenues by Customer Group
    (In thousands)
                                      Three Months Ended   Nine Months Ended
                                         December 31,        December 31,
                                        --------------       ------------
                                        2009      2008      2009      2008
                                        ----      ----      ----      ----
    Medical Market                     $5,172    $7,175   $17,280   $19,719
    Veterinary Market                  23,889    17,907    67,396    54,465
    Other                               1,944     1,882     6,216     5,040
                                        -----     -----     -----     -----
    Total revenues                    $31,005   $26,964   $90,892   $79,224
                                      =======   =======   =======   =======

SOURCE Abaxis, Inc.

RELATED LINKS
http://www.abaxis.com

'/>"/>

SOURCE Abaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Abaxis, Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference
2. Abaxis, Inc. to Present at the Sidoti & Company Second Annual New York Institutional Investor Forum
3. Abaxis to Report Second Quarter Fiscal 2010 Financial Results Tuesday, October 27, 2009
4. ABAXIS Announces Launch of the First Fully Automated Canine Wellness Profile That Includes a Canine Heartworm Antigen Test
5. Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
6. Encision Reports Profitable Third Fiscal Quarter Results
7. Zimmer Reports Fourth Quarter and 2009 Financial Results
8. Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results
9. Lilly Reports Fourth-Quarter and Full-Year 2009 Results
10. P&G Reports Accelerated Sales and Unit Volume Growth
11. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Ampio Pharmaceuticals, Inc. (NYSE MKT: ... entered into a Controlled Equity Offering SM Sales ... Michael Macaluso , Chairman and CEO, stated "During ... are not currently raising money and that we have ... 2017 and still complete all of our current objectives ...
(Date:2/11/2016)... Germany , February 11, 2016 ... up 6.8% to EUR 1,377.2m  Adjusted EBITDA climbs to ... 18.0% to EUR 3.41  Proposed dividend of EUR 0.85 ... sale of glass tubing business and refinancing successfully completed  ... to 5% on organic basis  Adjusted EBITDA expected ...
(Date:2/10/2016)... REDWOOD CITY, Calif., Feb. 10, 2016   Genomic Health, Inc. ... progress for the quarter and year ended December 31, 2015. ... in the fourth quarter of 2015, compared with $69.1 million in ... a constant currency basis, revenue increased 9 percent compared with the ... --> U.S. revenue was $63.9 million in the fourth ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... ... the American Academy of Dermatology Annual Meeting at the Walter E. Washington Convention ... raise awareness for both the condition of hyperhidrosis (excessive sweating) and its treatment ...
(Date:2/11/2016)... ... 11, 2016 , ... Husted Kicking has completed its Third Annual ... 6th & 7th, 2016 according to kicking coach Michael Husted. , “This event serves ... NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third party organization to ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... The book, ... for IT services, what questions to ask your IT consultant before signing a contract ... to your computer network. , “With companies relying heavily on e-mail and technology, it’s ...
(Date:2/11/2016)... ... , ... As part of their 2015 end of year funding strategy, ... has gifted $10,000 to University of Chicago to support ovarian cancer research being conducted ... are honored to support a promising young investigator from Dr. Lengyel’s lab at the ...
(Date:2/10/2016)... City, California (PRWEB) , ... February 10, 2016 ... ... Imaging Society (WMIS), known as the World Molecular Imaging Congress (WMIC), will be ... theme for the 2016 meeting is “Imaging Biology…Improving Therapy.” The congress will highlight ...
Breaking Medicine News(10 mins):